October 16, 2019 10:38 AM EDTUpdated 11:15 AM

Amarna raises €10M to push gene therapy platform into clinic; Editas Medicine, AskBio join forces

Kathy Wong

Editor

→ Amarna Therapeutics — developing an SV40-based gene delivery vector platform called SVac — has raised €10 million. The round was led by Swedish investment company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amarna raises €10M to push gene therapy platform into clinic; Editas Medicine, AskBio join forces

Kathy Wong

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Amar­na rais­es €10M to push gene ther­a­py plat­form in­to clin­ic; Ed­i­tas Med­i­cine, AskBio join forces

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Amarna raises €10M to push gene therapy platform into clinic; Editas Medicine, AskBio join forces